Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan

MT Newswires Live

2025/12/31

Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.

The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.

Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2595574913"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595574913\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595574913?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 09:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595574913","market":"sh","top_or_hot":-1,"title":"Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan","media":"MT Newswires Live","content":"<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.</p><p>The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.</p><p>Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-31 09:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.</p><p>The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.</p><p>Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0114","symbol_name":"健康中国","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2595574913","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595574913","pubTimestamp":1767143284,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Livzon Pharmaceutical Group  has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm , raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry  said in a Shanghai Stock Exchange filing on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600380":"健康元","BK0114":"健康中国","BK0077":"质押式回购","01513":"丽珠医药","BK0046":"生物疫苗","BK1191":"制药","BK0187":"一线龙头","BK0028":"国家队","000513":"丽珠集团","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"丽珠医药对越南Imexpharm发起要约收购出价上调至18.5亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600380":0.9,"01513":0.9,"000513":0.9},"content_text":"Livzon Pharmaceutical Group (HKG:1513, SHE:000513) has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm (HOSE:IMP), raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry (SHA:600380) said in a Shanghai Stock Exchange filing on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}